8-KMaterial AgreementsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Jul 19, 2005)

Filed July 19, 2005For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on July 18, 2005, reporting a significant material definitive agreement. The company, along with Royalty Pharma, entered into a Royalty Sale Agreement to purchase all royalties payable by Gilead under an existing license agreement with Emory University. This transaction involves a total purchase price of $525 million, with Gilead contributing $341.25 million (65%) and Royalty Pharma contributing $183.75 million (35%). This agreement effectively restructures the royalty payments for the licensed intellectual property. Gilead will now pay 35% of the previously Emory-owed royalties directly to Royalty Pharma. The transaction is contingent upon certain closing conditions, including the amendment and restatement of the license agreement to incorporate Royalty Pharma and an additional $15 million payment from Gilead to Emory in connection with the agreement amendment. This move suggests Gilead is seeking to manage its future royalty obligations and potentially free up capital.

Key Highlights

  • 1Gilead Sciences entered into a Royalty Sale Agreement on July 18, 2005.
  • 2The agreement involves the purchase of all royalties payable by Gilead under a license with Emory University.
  • 3The total purchase price for these royalties is $525 million.
  • 4Gilead will pay $341.25 million (65% of the total price) towards the purchase.
  • 5Royalty Pharma will pay $183.75 million (35% of the total price) towards the purchase.
  • 6Following the transaction, Gilead will pay 35% of the former Emory royalty amount directly to Royalty Pharma.
  • 7The transaction is subject to customary closing conditions, including amendment of the license agreement and an additional $15 million payment to Emory.

Frequently Asked Questions

The primary purpose of this agreement is for Gilead Sciences and Royalty Pharma to acquire all future royalty payments that Gilead owes to Emory University under a specific license agreement. This effectively reallocates the royalty stream, with Royalty Pharma now receiving a significant portion.

Gilead is paying a substantial amount ($341.25 million) upfront to acquire the royalty stream. Going forward, Gilead's royalty obligation to Emory will be reduced, with 35% of those former royalty payments now being directed to Royalty Pharma. This likely aims to restructure or cap future cash outflows related to these royalties.

Key conditions include the amendment and restatement of the original license agreement to include Royalty Pharma as a recipient, the execution of a conveyance agreement between Emory and Royalty Pharma, and Gilead's payment of an additional $15 million to Emory in connection with the amended agreement. Standard closing conditions also apply.

This 8-K filing primarily concerns the financial arrangement of existing royalty payments related to intellectual property licensed from Emory University. It does not explicitly detail the specific drug or technology involved, nor does it announce new research or development activities.